CD274 and neoplasm: Immunotherapeutic resistance, on the other hand, involves overexpression of immune checkpoint molecules (e.g., PD-L1), immunosuppressive effects of the tumor microenvironment (e.g., enrichment of M2-type macrophages and Treg cells), and reduced expression of tumor antigens (14, 15).